drugset / Trial / NCT05367492

Varenicline for Nicotine Vaping Cessation in Adolescents

NCT05367492 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

The study will test the hypothesis that varenicline, when added to behavioral and texting support for vaping cessation, will improve vaping abstinence rates in adolescents dependent on vaped nicotine over placebo plus behavioral and texting support for vaping cessation. Approximately 225 adolescents will be randomly assigned to one of three arms (1) varenicline up to 1 mg bid for 12 weeks plus behavioral and texting support for vaping cessation (V+BC), (2) identical appearing placebo plus behavioral and texting support (P+BC) and (3) enhanced usual care (EUC). The primary comparison will be the double-blind, placebo-controlled comparison of vaping cessation rates in those assigned to varenicline vs placebo.

Timeline

Start
2022-06-22
Primary completion
2024-03-20
Completion
2024-05-28

Outcome

Met primary endpoint

registry analysis (superiority test); Double Blind Varenicline (V+BC) vs Double Blind Placebo (P+BC); p <0.001; Odds Ratio (OR) 6.5 (95% CI 3.0 to 14.1); Regression, Logistic NCT05367492 ↗

paper continuous abstinence rates were 51% vs 14% during weeks 9 through 12 (adjusted odds ratio [aOR], 6.5 [95% CI, 3.0-14.1]; P < .001) PMID 40266580 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Varenicline Small molecule 0.5 mg —
Subject Varenicline Small molecule 1 mg —

Indications